Accelerating cell and gene therapy development
As cell and gene therapies show increasing promise for improving patient care, the need to overcome the complex manufacturing and delivery model is vital if the pharma industry intends to keep pace with market demands
Add bookmark
Over the past three decades we have seen rapid advancements in the capabilities of cell and gene therapies (CGTs). Today, they are at the forefront of innovative healthcare, with applications for the treatment of severe diseases such as cancer or blindness.
However, pharma organizations have struggled with creating successful business models for CGTs, with some researchers noting that 95 per cent of patients receive treatments through commercial delivery. This report created by Pharma IQ produced in collaboration with Entegris draws on the insights and experience of industry professionals from organizations the likes of Entegris, AstraZeneca and PPD. It outlines the challenges that prevent the acceleration of CGT development, including manufacturing and scaling, and offer solutions for overcoming them.
Download this report to uncover:
- The primary challenges of bringing CGT to market and how to overcome them.
- Best practice solutions for manufacture and delivery of treatments.
- Real-world examples of manufacturing solutions in practice.
